| __timestamp | Celldex Therapeutics, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 14400000 |
| Thursday, January 1, 2015 | 4011000 | 33800000 |
| Friday, January 1, 2016 | 102026000 | 35900000 |
| Sunday, January 1, 2017 | 96171000 | 1254000 |
| Monday, January 1, 2018 | 66449000 | 4889000 |
| Tuesday, January 1, 2019 | 42672000 | 7400000 |
| Wednesday, January 1, 2020 | 42534000 | 10100000 |
| Friday, January 1, 2021 | 3068000 | 14300000 |
| Saturday, January 1, 2022 | 1400000 | 23200000 |
| Sunday, January 1, 2023 | 3008000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding financial health is crucial. This analysis delves into the cost of revenue trends for Neurocrine Biosciences, Inc. and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Celldex Therapeutics experienced significant fluctuations, with a peak cost of revenue in 2016, nearly 70% higher than its lowest point in 2022. In contrast, Neurocrine Biosciences showed a more stable trajectory, with a gradual increase, culminating in a 175% rise from 2014 to 2023. These trends highlight the contrasting financial strategies and market responses of these two companies. While Celldex's costs reflect a volatile market presence, Neurocrine's steady growth suggests a more consistent operational strategy. This data offers valuable insights for investors and industry analysts seeking to understand the financial dynamics of the biotech sector.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Merck & Co., Inc. and Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Catalent, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Exelixis, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Neurocrine Biosciences, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs MiMedx Group, Inc.